How Bain plans to deploy $1B new fund

Bain Capital’s larger second fund could see firm increasing emphasis on investing in big biopharma spinouts

Bain Capital Life Sciences’ larger second fund could see the firm increasing its emphasis on investing in big biopharma spinouts after its debut fund featured investments in a pair of megarounds by Pfizer spin-offs.

Bain Capital’s Jeffrey Schwartz told BioCentury the

Read the full 415 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE